Considering the increased expression of innate immunity mediators in TABs, and the inhibitory effect on IL-6 production exerted by GC and 5Z-7-oxozeanol in fibrinogen- or SAA-treated immune cells, we speculate about the potential therapeutic effect of TLR antagonists (such as hydroxychloroquine for TLR7) to reduce the inflammation in GCA. This evidence concerns the gene IL6 and temporal arteritis.